Integra LifeSciences (NASDAQ:IART) Shares Down 4.4% - What's Next?

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report)'s stock price fell 4.4% on Monday . The stock traded as low as $21.61 and last traded at $22.15. 303,470 shares were traded during trading, a decline of 11% from the average session volume of 341,422 shares. The stock had previously closed at $23.17.

Analysts Set New Price Targets

A number of equities research analysts have commented on IART shares. Bank of America decreased their price objective on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research report on Monday, October 7th. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a report on Monday, October 14th. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research note on Tuesday, November 5th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price for the company. Finally, BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Trading Down 6.3 %

The company has a fifty day simple moving average of $23.22 and a two-hundred day simple moving average of $22.83. The company has a market capitalization of $1.67 billion, a P/E ratio of -241.08, a price-to-earnings-growth ratio of 0.82 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the business earned $0.76 EPS. The firm's revenue was down .4% compared to the same quarter last year. On average, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares of the company's stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 3.10% of the company's stock.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. raised its stake in Integra LifeSciences by 18.7% during the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after purchasing an additional 63,266 shares during the last quarter. Versor Investments LP acquired a new position in shares of Integra LifeSciences during the third quarter valued at about $612,000. BNP Paribas Financial Markets lifted its stake in shares of Integra LifeSciences by 824.5% in the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock valued at $2,031,000 after buying an additional 99,685 shares during the period. GSA Capital Partners LLP acquired a new stake in Integra LifeSciences during the third quarter worth about $960,000. Finally, Point72 Europe London LLP increased its stake in Integra LifeSciences by 13.8% during the second quarter. Point72 Europe London LLP now owns 546,035 shares of the life sciences company's stock valued at $15,911,000 after acquiring an additional 66,400 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.